Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or ...
17h
FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Applicat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results